Wierda WG, Kipps TJ, Al-Sawaf O, Chyla B, et al. Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL. Leuk Lymphoma 2022;63:2765-2784.
PMID: 35983732